癌症免疫治療藥品—Pembrolizumab之介紹

A New Immunotherapy for Cancer Treatment

郭俊男(Chun-Nan Kuo)

《腫瘤護理雜誌》 16卷2期 (2016/12) Pp. 29-34

https://doi.org/10.3966/168395442016121602003

摘要

癌細胞會表現抗原，T細胞辨識之後可攻擊癌細胞，但因為PD1/PD-L1的負向調控作用，會使T細胞去活性。Pembrolizumab為作用在PD1的單株抗體，可抑制此負向調控，達到抑制腫瘤生長作用。目前在黑色素瘤、非小細胞肺癌及鱗狀上皮細胞頭頸癌的臨床試驗均展現了優於傳統化學治療的效果。因其調節免疫的作用，也帶來了一些免疫相關不良反應，包括皮疹、腹瀉、結腸炎、肝炎、肺炎、甲狀腺功能不全等，嚴重時須使用類固醇或免疫抑制劑治療。因此在治療過程中應密切監測相關檢驗數值或臨床症狀。

關鍵字

Pembrolizumab ； 免疫治療 ； 黑色素瘤 ； 非小細胞肺癌 ； 頭頸癌

並列摘要

T cells can attack tumors because they can recognize the antigens expressed by the tumor cells during the process of carcinogenesis. But the activity of T cells is diminished through negative regulation, such as PD-1 and PD-L1 interaction. Pembrolizumab is a humanized antibody which binds to PD-1and inhibits the negative regulation of T cells thereby interferes the growth of tumor cells. Clinical trials of melanoma, non-small cell lung cancer and squamous cell head and neck cancer have been done and the results demonstrated superior efficacy compared to standard chemotherapy. Because of the immune regulation, pembrolizumab could induce immune-related adverse events, such as rash, diarrhea, colitis, hepatitis, pneumonitis and hypothyroidism. Corticosteroid and immune suppressant are needed when the symptoms of adverse event are severe. It is important to monitor related laboratory data and symptoms during the treatment course.

並列關鍵字

pembrolizumab ； immune therapy ； melanoma ； non-small cell lung cancer ； head and neck cancer

參考文獻

Schumacher T. N., & Schreiber R. D. (2015) Neoantigens in cancer immunotherapy. Science, 348(6230), 69-74.

Alexandrov, L. B., Nik-Zainal, S., Wedge D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., ... Stratton, M. R. (2013). Signatures of mutational processes in human cancer. Nature, 500(7463), 415-421.

Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1), 1-10.

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., ... Chen, L. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine, 8(8), 793-800.

Patnaik, A., Kang, S. P, Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., ... Tolcher, A. W. (2015). Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 21(19), 4286-4293